Kaken Pharmaceutical said on November 15 that it has formed a collaboration and option pact with Numab Therapeutics to develop the Swiss biotech’s potential first-in-class multi-specific antibody ND081 for the treatment of inflammatory bowel disease (IBD).Under the deal, Numab will…
To read the full story
Related Article
- Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
November 14, 2025
BUSINESS
- Japan Pharma Workforce Up Slightly; Generic Firms Drive Gains over 5 Years
April 10, 2026
- Zenyaku, Chugai to End Rituxan Co-Promotion in September
April 10, 2026
- Effexor’s GAD Nod Seen Boosting Diagnosis, Treatment in Japan: Expert
April 10, 2026
- MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
- Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
April 9, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





